1510 Clinical implications of C-reactive protein as a prognostic marker in advanced cancer patients in palliative settings

Background: Advanced cancer patients are part of a group likely to be more susceptible to COVID-19. Aims: To describe the profile of advanced cancer inpatients to an exclusive Palliative Care Unit (PCU) with the diagnosis of COVID-19, and to evaluate the factors associated with death in these cases. Design: Retrospective cohort study with data from advanced cancer inpatients to an exclusive PCU, from March to July 2020, with severe acute respiratory syndrome. Diagnostic of COVID-19 and death were the dependent variables. Logistic regression analyses were performed, with the odds ratio (OR) and 95% confidence interval (CI). Results: One hundred fifty-five patients were selected. The mean age was 60.9 (±13.4) years old and the most prevalent tumor type was breast (30.3%). Eighty-three (53.5%) patients had a diagnostic confirmation of COVID-19. Having diabetes mellitus (OR: 2.2; 95% CI: 1.1-6.6) and having received chemotherapy in less than 30 days before admission (OR: 3.8; 95% CI: 1.2-12.2) were associated factors to diagnosis of COVID-19. Among those infected, 81.9% died and, patients with Karnofsky Performance Status (KPS) < 30% (OR: 14.8; 95% CI 2.7-21.6) and C-reactive protein (CRP) >21.6mg/L (OR: 9.3; 95% CI 1.1-27.8), had a greater chance of achieving this outcome. Conclusion: Advanced cancer patients who underwent chemotherapy in less than 30 days before admission and who had diabetes mellitus were more likely to develop Coronavirus 2019 disease. Among the confirmed cases, those hospitalized with worse KPS and bigger CRP were more likely to die.

Download Full-text

MO1-1 Lymphocyte-C-reactive protein ratio as a prognostic marker in rectal cancer patients with neoadjuvant chemoradiotherapy

Annals of Oncology ◽

10.1016/j.annonc.2021.05.559 ◽

2021 ◽

Vol 32 ◽

pp. S294

Author(s):

Yoshinaga Okugawa ◽

Hiroyuki Fujikawa ◽

Yusuke Omura ◽

Akira Yamamoto ◽

Takahito Kitajima ◽

...

Keyword(s):

Rectal Cancer ◽

Cancer Patients ◽

Prognostic Marker ◽

Neoadjuvant Chemoradiotherapy ◽

C Reactive Protein ◽

Protein Ratio ◽

Reactive Protein

Download Full-text

Clinical implications of the preoperative lymphocyte C-reactive protein ratio in esophageal cancer patients

Surgery Today ◽

10.1007/s00595-020-02166-5 ◽

2020 ◽

Author(s):

Akira Yamamoto ◽

Yuji Toiyama ◽

Yoshinaga Okugawa ◽

Takashi Ichikawa ◽

Hiroki Imaoka ◽

...

Keyword(s):

Esophageal Cancer ◽

Cancer Patients ◽

Clinical Implications ◽

C Reactive Protein ◽

Protein Ratio ◽

Reactive Protein

Download Full-text

Prognostic value of lymphocyte-to-C-reactive protein ratio in patients with gastric cancer after surgery: a multicentre study

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyaa099 ◽

2020 ◽

Vol 50 (10) ◽

pp. 1141-1149 ◽

Cited By ~ 1

Author(s):

Chuan-bing Cheng ◽

Qu-xia Zhang ◽

Lv-Ping Zhuang ◽

Jian-wei Sun

Keyword(s):

Gastric Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Prognostic Marker ◽

Predictive Value ◽

Radical Gastrectomy ◽

C Reactive Protein ◽

Protein Ratio ◽

Reactive Protein ◽

Gastric Cancer Patients

Abstract Objective The immune inflammation-based score is recognized as a prognostic marker for cancer. However, the most accurate prognostic marker for patients with gastric cancer remains undetermined. We aimed to evaluate the predictive value of the lymphocyte-to-C-reactive protein ratio for outcomes in gastric cancer patients after radical gastrectomy. Methods A total of 607 gastric cancer patients treated at three Chinese institutions were included. Receiver operating characteristic curves were generated, and the areas under the curve were calculated to compare the predictive value among the inflammation-based score, lymphocyte-to-C-reactive protein ratio, C-reactive protein/albumin and neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios. Cox regression was performed to determine the prognostic factors for overall survival. Results The median follow-up time was 63 months (range: 1–84 months). The optimal cut-off value for lymphocyte-to-C-reactive protein ratio was 0.63. The patients were divided into the LCR <0.63 (LLCR, n = 294) group and the LCR ≥0.63 (HLCR, n = 313) group. LLCR was significantly correlated with poor clinical characteristics. Compared with inflammation-based score, lymphocyte-to-C-reactive protein ratio had the highest areas under the curve (0.695). Patients with LLCR experienced more post-operative complications than the HLCR group (20.4 vs. 12.1%, P = 0.006). Multivariate analysis showed that a higher lymphocyte-to-C-reactive protein ratio (HR: 0.545, 95%CI: 0.372–0.799, P = 0.002) was associated with better overall survival. The HLCR group had higher 5-year overall survival rate than the LLCR group (80.5 vs. 54.9%, P < 0.001). Conclusions Preoperative lymphocyte-to-C-reactive protein ratio levels can effectively predict the short-term and oncological efficacy of gastric cancer patients after radical gastrectomy with a predictive value significantly better than other inflammation-based score.

Download Full-text